Infex Therapeutics announces positive phase IIa study results for RESP─X in NCFB patients colonised with Pseudomonas aeruginosa

Infex Therapeutics, a leader in critical─priority infectious diseases, with a broad and diverse pipeline of innovative best─in─class and first─in─class drug candidates to address the urgent global shortage of novel